ERBB2 and breast carcinoma: Here, we discovered a heregulin-dependent HER3 oncogenic signaling nexus, which forms the basis of a feed-forward loop supporting SorLA, HER2, and HER3 levels in breast cancer cells to drive neratinib resistance (Fig. 7G).